Clinical characteristics and survival analysis of cancer of unknown primary

Ma,Minting; Guo,Bin; Duan,Qiuli; Jiao,Pengqing; Bi,Junfang; Wei,Suju; Wang,Junyan; Zhang,Fan; Xu,Yu; Zhang,Panpan; He,Ming; Jin,Jing

doi:10.3892/ol.2025.14929

Clinical characteristics and survival analysis of cancer of unknown primary

Authors:
- Minting Ma
- Bin Guo
- Qiuli Duan
- Pengqing Jiao
- Junfang Bi
- Suju Wei
- Junyan Wang
- Fan Zhang
- Yu Xu
- Panpan Zhang
- Ming He
- Jing Jin
View Affiliations

Affiliations: Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Anorectum Surgical, Traditional Chinese Medicine Hospital of Shijiazhuang City, Shijiazhuang, Hebei 050051, P.R. China, Department of Immunology and Rheumatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Combined Traditional Chinese Medicine and West Medicine, Traditional Chinese Medicine Hospital of Shijiazhuang City, Shijiazhuang, Hebei 050051, P.R. China, Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, 100142, P.R. China, Institute of Cancer, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
Published online on: February 13, 2025 https://doi.org/10.3892/ol.2025.14929
Article Number: 185
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer of unknown primary (CUP) is a diagnosis that the primary lesion cannot be confirmed by a series of imaging, endoscopic and pathological examinations. The present study aimed to assess the clinical characteristics and survival outcomes of patients with CUP. The present retrospective observational study included patients diagnosed with malignancies confirmed as CUP using histopathology at the Oncology Department of the Fourth Hospital of Hebei Medical University (Shijiazhuang, China) from January 2009 to January 2021. Clinical and pathological data, genetic testing results, treatment modalities and median overall survival (OS) were analyzed. A total of 107 patients were included, with a mean age of 56.59 years. The median follow‑up period was 48.8 months. Adenocarcinoma was the most common pathological type (38.3%), followed by squamous cell carcinoma (31.8%) and neuroendocrine carcinoma (16.8%). The median OS was 28.4 months, with 1‑, 2‑, 3‑ and 4‑year OS rates of 68.2, 54.1, 48.4 and 42.3%, respectively. Imaging revealed that 31 patients (29%) had visceral metastases, and these patients had a significantly shorter median OS compared with those without visceral metastases (8.9 vs. 69 months; P=0.001). Patients who received local treatment (n=31; 29%) had significantly longer survival times than those who did not (69 vs. 17.9 months; P=0.009). Of the 107 patients, 101 (94.4%) received systemic treatment. The median OS times for different treatment groups were as follows: Chemotherapy alone, 28.4 months; chemotherapy combined with immune checkpoint inhibitors, anti‑angiogenic agents or targeted therapy, not reached; no chemotherapy, 8.0 months; and untreated, 9.4 months, with significant differences observed among the groups (P=0.008). The survival outcomes of patients with CUP varied based on the presence of visceral metastasis and the treatment modalities employed. Systemic treatments, particularly those incorporating targeted therapy, appear to have the potential to improve prognosis.

View Figures

View References

1	Levi F, Te VC, Erler G, Randimbison L and La Vecchia C: Epidemiology of unknown primary tumours. Eur J Cancer. 38:1810–1812. 2002. View Article : Google Scholar : PubMed/NCBI
2	Lee MS and Sanoff HK: Cancer of unknown primary. BMJ. 371:m40502020. View Article : Google Scholar : PubMed/NCBI
3	Pavlidis N, Briasoulis E, Hainsworth J and Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 39:1990–2005. 2003. View Article : Google Scholar : PubMed/NCBI
4	Pavlidis N and Fizazi K: Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol. 69:271–278. 2009. View Article : Google Scholar : PubMed/NCBI
5	Brustugun OT and Helland A: Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta Oncol. 53:134–137. 2014. View Article : Google Scholar : PubMed/NCBI
6	Boo YK, Park D, Lim J, Lim HS and Won YJ: Descriptive epidemiology of cancer of unknown primary in South Korea, 1999–2017. Cancer Epidemiol. 74:1020002021. View Article : Google Scholar : PubMed/NCBI
7	Rassy E and Pavlidis N: The currently declining incidence of cancer of unknown primary. Cancer Epidemiol. 61:139–141. 2019. View Article : Google Scholar : PubMed/NCBI
8	Ren M, Cai X, Jia L, Bai Q, Zhu X, Hu X, Wang Q, Luo Z and Zhou X: Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China. BMC Cancer. 23:11752023. View Article : Google Scholar : PubMed/NCBI
9	Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, et al: Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0). Cancer Sci. 109:2980–2985. 2018. View Article : Google Scholar : PubMed/NCBI
10	Thai AA, Solomon BJ, Sequist LV, Gainor JF and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
11	Erlander MG, Ma XJ, Kesty NC, Bao L, Salunga R and Schnabel CA: Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn. 13:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
12	Fizazi K, Greco FA, Pavlidis N and Pentheroudakis G; ESMO Guidelines Working Group, : Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26 Suppl 5:vi33–vi38. 2011.
13	Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ and Hainsworth JD: Molecular profiling in unknown primary cancer: Accuracy of tissue of origin prediction. Oncologist. 15:500–506. 2010. View Article : Google Scholar : PubMed/NCBI
14	Li Z, Li F, Pan C, He Z, Pan X, Zhu Q, Wu W and Chen L: Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma. Lung Cancer. 154:69–75. 2021. View Article : Google Scholar : PubMed/NCBI
15	Sun X and Kaufman PD: Ki-67: More than a proliferation marker. Chromosoma. 127:175–186. 2018. View Article : Google Scholar : PubMed/NCBI
16	Wei B, Kang J, Kibukawa M, Arreaza G, Maguire M, Chen L, Qiu P, Lang L, Aurora-Garg D, Cristescu R and Levitan D: Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden and clinical utility for predicting response to pembrolizumab. J Mol Diagn. 24:600–608. 2022. View Article : Google Scholar : PubMed/NCBI
17	Society of Cancer of Multiple and Unknown Primary of China Anti-Cancer Association, . China Anti-Cancer Association guideline for diagnosis and treatment of cancer of multiple and unknown primaries (2023 edition). Chin Oncol. 33:403–422. 2023.
18	Greco FA, Lennington WJ, Spigel DR and Hainsworth JD: Molecular profiling diagnosis in unknown primary cancer: Accuracy and ability to complement standard pathology. J Natl Cancer Inst. 105:782–790. 2013. View Article : Google Scholar : PubMed/NCBI
19	Weiss LM, Chu P, Schroeder BE, Singh V, Zhang Y, Erlander MG and Schnabel CA: Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn. 15:263–269. 2013. View Article : Google Scholar : PubMed/NCBI
20	Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M and Huebner G: Comparison of histopathological and gene expression-based typing of cancer of unknown primary. Virchows Arch. 456:23–29. 2010. View Article : Google Scholar : PubMed/NCBI
21	Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser M, et al: A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist. 17:801–812. 2012. View Article : Google Scholar : PubMed/NCBI
22	Rassy E and Pavlidis N: Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol. 17:541–554. 2020. View Article : Google Scholar : PubMed/NCBI
23	Meijer L, Verhoeven RHA, de Hingh IHJT, van de Wouw AJ, van Laarhoven HWM, Lemmens VEPP and Loef C: Extensive diagnostic work-up for patients with carcinoma of unknown primary. Clin Exp Metastasis. 38:231–238. 2021. View Article : Google Scholar : PubMed/NCBI
24	Beauchamp K, Moran B, O'Brien T, Brennan D, Crown J, Sheahan K and Cotter MB: Carcinoma of unknown primary (CUP): An update for histopathologists. Cancer Metastasis Rev. 42:1189–1200. 2023. View Article : Google Scholar : PubMed/NCBI
25	Joerger AC, Stiewe T and Soussi T: TP53: The unluckiest of genes? Cell Death Differ. Oct 23–2024.(Epub ahead of print). PubMed/NCBI
26	Bochtler T, Reiling A, Endris V, Hielscher T, Volckmar AL, Neumann O, Kirchner M, Budczies J, Heukamp LC, Leichsenring J, et al: Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. Int J Cancer. 146:3053–3064. 2020. View Article : Google Scholar : PubMed/NCBI
27	Gerard L, Garcia J, Gauthier A, Lopez J, Durand A, Hervieu V, Lemelin A, Chardon L, Landel V, Gibert B, et al: ctDNA in neuroendocrine carcinoma of gastroenteropancreatic origin or of unknown primary: The CIRCAN-NEC pilot study. Neuroendocrinology. 111:951–964. 2021. View Article : Google Scholar : PubMed/NCBI
28	Bytnar JA, Lin J, Moncur JT, Shriver CD and Zhu K: Cancers of unknown primary: Survival by histologic type, demographic features, and treatment in the U.S. Military Health System. Cancer Epidemiol. 82:1023162023. View Article : Google Scholar : PubMed/NCBI